BusinessAdaptimmune Reports Fourth Quarter / Full Year 2017 Financial Results and Business UpdateBy Nasdaq OMXMar 15, 2018, 11:30 AM UTC
BusinessAdaptimmune Announces Responses in Second Solid Tumor Indication with NY-ESO SPEAR T-cellsBy Nasdaq OMXMar 15, 2018, 11:30 AM UTC
BusinessTESARO Announces Data Presentations at the 2018 American Association for Cancer Research Annual MeetingBy Nasdaq OMXMar 14, 2018, 8:50 PM UTC
BusinessCrownBio Enters Strategic Partnership with Phanes Therapeutics to Accelerate Discovery and Development of Phanes’ Novel Oncology AgentsBy Nasdaq OMXMar 13, 2018, 12:00 PM UTC
BusinessVBI Vaccines Announces Voluntary Delisting from the Toronto Stock ExchangeBy Nasdaq OMXMar 12, 2018, 8:15 PM UTC
BusinessCrown Bioscience to Showcase Scientific Expertise at Cambridge UK Symposium: Preclinical Evaluation of Novel ImmunotherapiesBy Nasdaq OMXMar 9, 2018, 1:02 PM UTC
BusinessAdaptimmune to Report Fourth Quarter / Full Year 2017 Financial Results and Business Update on Thursday March 15, 2018By Nasdaq OMXMar 5, 2018, 5:12 PM UTC
BusinessWebinar to Reveal Data Supporting the Use of MuScreen™ for Preclinical Immunotherapeutic DevelopmentBy Nasdaq OMXFeb 27, 2018, 1:01 PM UTC
